Introduction {#S1}
============

Catheter ablation is an effective and established rhythm control strategy in patients with anti-arrhythmic drug-resistant atrial fibrillation (AF) ([@B2]). Nevertheless, catheter ablation of persistent AF (PeAF) or longstanding PeAF is a challenging procedure, and the post-procedural recurrence rate is still substantially high ([@B30]). This is because extra-pulmonary vein (PV) triggers are more common in patients with PeAF ([@B22]), but they cannot be treated with circumferential PV isolation (CPVI) alone. Thus, empirical extra-PV ablation for substrate modification strategies has been applied for patients with PeAF ([@B32]) and has been shown to be beneficial ([@B15]). Linear ablation may improve the rhythm outcome by a reduction in the critical mass and exit block of extra-PV triggers, despite the difficulty to obtain long-lasting bidirectional block of linear lesions ([@B14]). Whereas, a randomized clinical trial failed to prove the beneficial effect of empirical extra-PV ablation compared to the CPVI in patients with PeAF ([@B30]). Therefore, personalized, focused, and effective ablation strategies are required, rather than a routine empirical extra-PV left atrial (LA) ablation with extensive cardiac tissue damage.

Recently, computational modeling has been making remarkable progress, and its clinical usefulness is gradually increasing. Computational AF modeling reflecting a sophisticated histology such as fibrosis and a personalized fiber orientation using magnetic resonance imaging (MRI)-late gadolinium enhancement has been developed and is now applicable to clinical data ([@B12]; [@B28]). Because the wave-dynamics mechanism of AF is highly affected by the atrial anatomy and surface curvature ([@B26]), we hypothesized that a customized extra-PV ablation according to the anatomy of the atrium would reduce the recurrence rate after PeAF or longstanding PeAF ablation. The purpose of this study was to evaluate the effect of a computational modeling-guided AF ablation to improve the rhythm outcome of PeAF ablation as compared to an empirical treatment conducted by experts. Five different linear and electrogram-guided virtual ablation methods were tested with an AF modeling reflecting the patients left atrial (LA) anatomy obtained from heart computed tomography (CT) images before the procedure. The pre-determined lesion set with the best virtual AF termination was provided to operators of the computational modeling-guided ablation group; however, the operators of the empirical ablation group were blinded to the simulation outcome.

Materials and Methods {#S2}
=====================

Study Design and Population {#S2.SS1}
---------------------------

This study was a randomized, open-label, multicenter trial involving patients with non-valvular AF undergoing catheter ablation ([ClinicalTrials.gov](http://clinicaltrials.gov); NCT 02171364). The study protocol adhered to the Declaration of Helsinki and was approved by the institutional review board of each participating center. Written informed consent was obtained from all patients. The study design and results of the CUVIA-AF 1 trial have been reported ([@B25]). The study cohort included 118 patients (77⋅8% men, age 60⋅8 ± 9⋅9 years) who underwent catheter ablation of symptomatic and drug-refractory non-valvular PeAF at six tertiary hospitals in Korea. Key exclusion criteria were as follows: (1) patients younger than 20 or older than 80 years; (2) valvular AF; (3) significant structural heart disease other than left ventricular hypertrophy; (4) an LA diameter of 60 mm or more, and (5) a history of previous AF ablation or cardiac surgery. The anatomy of the LA and PVs was visually defined by three-dimensional (3D) CT scans (64 Channel, Light Speed Volume CT, Philips, Brilliance 63, Amsterdam, Netherlands). All anti-arrhythmic drugs (AADs) were discontinued for a period of at least five half-lives.

The enrolled patients were randomly assigned to either the computational modeling-guided ablation group or the empirical ablation group ([Figure 1](#F1){ref-type="fig"}). For all patients in both groups, digital images and communication in medicine (DICOM) files of the cardiac CT images were sent to the core lab, and AF modeling and virtual ablation tests were conducted before the clinical AF ablation. The ablation lesion sets were categorized by applying the following five strategies: (1) CPVI alone, (2) CPVI and an additional posterior box lesion (POBI) ([@B10]; [@B14]), (3) additional POBI and an anterior linear (AL) ablation ([@B25]), (4) additional roof line (RL) and a left lateral isthmus (LLI) line ([@B7]), and (5) an additional complex fractionated atrial electrogram (CFAE)-guided ablation ([@B20]; [@B10]). Among the five different ablation lesions, the best virtual ablation lesion set was determined by the earliest termination of the virtual AF with the simulation modeling study. For patients in the computational modeling-guided ablation group, the operator was informed about the best virtual ablation strategy and applied the clinical AF ablation procedure. In the empirical ablation group, the ablation lesion set was selected by the operator based on his or her experience. The primary end point was AF recurrence after a single procedure, and the secondary end point was a recurrence pattern, the response to AADs, and the cardioversion rate. All ablation procedures were performed by physicians with at least 10 years of experience.

![Study flow diagram. The enrolled patients were randomly assigned to either the computational modeling-guided ablation group or the empirical ablation group. PeAF, persistent atrial fibrillation; RFCA, radiofrequency catheter ablation.](fphys-10-01512-g001){#F1}

Computational Modeling of AF {#S2.SS2}
----------------------------

After receiving consent from the patients, DICOM files of the heart CT images were sent to the core laboratory the night before or early in the morning of the AF ablation procedure. The patient randomization, computational AF modeling, and virtual AF ablation were performed at the core laboratory during working hours (9 a.m.--6 p.m.). Among 118 patients, four were excluded for incorrect selection and six were excluded due to a failed virtual AF ablation due to DICOM file errors or communication errors. Finally, 108 patients were enrolled and randomly assigned into two groups: 53 in the computational modeling-guided ablation group and 55 in the empirical ablation group ([Figure 1](#F1){ref-type="fig"}). The patient characteristics are shown in [Table 1](#T1){ref-type="table"}.

###### 

Baseline clinical characteristics.

                                            **Overall (*N* = 108)**   **Simulation-guided ablation (*N* = 53)**   **Empirical ablation (*N* = 55)**   ***p*-Value**
  ----------------------------------------- ------------------------- ------------------------------------------- ----------------------------------- ---------------
  Age (years)                               60.8 ± 9.6                59.7 ± 10.1                                 61.9 ± 9.6                          0.240
  Male, *n* (%)                             (76.9%)                   (75.5%)                                     (78.2%)                             0.821
  Longstanding persistent AF (%)            (77.8%)                   (83.0%)                                     (72.7%)                             0.249
  AF duration                               44.1 ± 55.6               39.4 ± 58.1                                 48.3 ± 53.5                         0.441
  Follow-up duration, months                31.5 ± 9.4                31.7 ± 9.3                                  31.3 ± 9.5                          0.830
  BMI (kg/m^2^)                             25.3 ± 3.1                25.7 ± 3.5                                  24.8 ± 2.6                          0.129
  CHA~2~DS~2~--VASc score                   2.0 ± 1.9                 1.9 ± 1.7                                   2.1 ± 1.9                           0.475
   Congestive heart failure (%)             (12.0%)                   (9.4%)                                      (14.5%)                             0.557
   Hypertension (%)                         (54.6%)                   (52.8%)                                     (56.4%)                             0.847
   Age ≥ 75 years (%)                       (9.3%)                    (3.8%)                                      (14.5%)                             0.094
   Age 65--74 years (%)                     (25.0%)                   (28.3%)                                     (21.8%)                             0.508
   Diabetes (%)                             (18.5%)                   (17.0%)                                     (20.0%)                             0.806
   Previous stroke (%)                      (28.7%)                   (28.3%)                                     (29.1%)                             \>0.999
   Previous TIA (%)                         (1.9%)                    (3.8%)                                      (0.0%)                              0.238
   Vascular disease (%)                     (13.0%)                   (9.4%)                                      (16.4%)                             0.392
  Echocardiographic parameters (Pre-RFCA)                                                                                                             
   LA diameter (mm)                         45.1 ± 4.4                46.1 ± 7.6                                  44.0 ± 4.4                          0.086
   LA volume index (mL/m^2^)                44.4 ± 14.8               45.0 ± 15.7                                 43.8 ± 14.0                         0.718
   LV EF (%)                                59.3 ± 9.7                57.8 ± 7.8                                  60.7 ± 9.7                          0.092
   E/Em                                     10.2 ± 4.7                9.6 ± 3.0                                   10.7 ± 4.7                          0.139

AAD, antiarrhythmic drug; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BSA, body surface area; E, early diastolic transmitral flow velocity; Em, early diastolic mitral annular velocity; ECV, electrical cardioversion; LA, left atrium; L-PeAF, long-standing persistent atrial fibrillation; LV EF, left ventricular ejection fraction; RFCA, radiofrequency catheter ablation; TIA, transient ischemic attack.

The LA geometries of the patients included were reconstructed from the 3D CT DICOM files defining the surface of the LA. A triangular mesh was generated with a prism-type element applying a constant thickness of 1.89 mm on the surface of the 3D LA geometry ([@B1]; [@B10]). The final number of grid elements was set between 400,000 and 500,000. The LA appendage structure and myocardial sleeves of the LA ([@B24]) were also included in the mesh. For the computational modeling of the cardiac wave propagation in the atrial wall, the following reaction-diffusion equation was used ([@B34]):
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where *Vm* (volt) is the membrane potential; β (meter^--1^) is the membrane surface-to-volume ratio; *Cm* (farad/meter^2^) is the membrane capacitance per unit area; *D* (siemens/meter) is the conductivity tensor; and *I*~*ion*~ and *I*~*s*~ (ampere/meter^2^) are the ion current and stimulation current, respectively. To simulate the reaction-diffusion system, we constructed the models using a generalized finite difference scheme which can effectively lower dimensionality and can reduce computing time with parallel computational modeling with graphics processing unit system ([@B34]).

For the calculation of ionic currents, a mathematical model of the human atrial action potential was used ([@B3]). Electrical stimulation was applied at the location of Bachmann's bundle, and reentry was initiated by rapid pacing: a total of 24 paces (eight paces per each pacing cycle length) with pacing cycle lengths of 200, 190, and 180 ms. The ionic currents in each cell were determined using the human atrial myocyte model applied by modified model from that of [@B3] To replicate the electrical remodeling associated with AF in the cell model, the conductances of I~*to*~, I~*CaL*~, I~*Kur*~, and I~*K*1~ were changed by −80, −40, −50, and +50%, respectively, as described previously by us ([@B25]) and others ([@B5]; [@B31]). We chose a conduction velocity (CV) of 0.4 m/s based on human patient data (Yonsei AF ablation cohort data; *n* = 1,980; mean CV = 0.43 ± 0.24 m/s) ([@B23]) and previous modeling studies ([@B10]).

Virtual AF Ablation {#S2.SS3}
-------------------

Virtual ablation was performed for all 108 patients in both the computational modeling-guided and empirical ablation groups. We developed a graphical user interface software, which had already been introduced ([@B25]), with which the user can perform virtual ablation by mouse-clicking on the atrial geometry (CUVIA, Model: SH01, ver. 1.0; Laonmed, Inc., Seoul, South Korea). The ablation patterns of each of the five protocols are shown in [Figure 2](#F2){ref-type="fig"}. At the ablated lesion points, the membrane potential was permanently set to the resting value (−80.6 mV) to generate conduction block. For the CFAE-guided ablation, the areas of CFAEs with a cycle length (CFAE CL) of less than 120 ms were ablated starting from the lowest CFAE CL area as long as the total ablated area was less than 5% of the total atrial area. Mitral annular area was set as non-conductive area. Virtual ablation was applied 4 s after the end of pacing. Computational modeling was applied for 25 s, and the duration lasted until the fibrillation termination was recorded for each ablation protocol. Virtual AF termination was determined as the time to the total extinction of the wavelet (90% repolarization) in the entire LA. A graphical user interface was developed using the C++ order to perform each virtual ablation on the virtual atrium of each patient.

![Five different protocols of virtual ablation. AL, left atrial anterior linear line; CFAE, complex fragmented atrial electrogram; CPVI, circumferential pulmonary vein isolation; LLI, left atrial left lateral isthmus line; POBI, posterior box isolation; Roof, left atrial roof line.](fphys-10-01512-g002){#F2}

Clinical AF Ablation {#S2.SS4}
--------------------

Electrophysiological mapping and radiofrequency catheter ablation (RFCA) have been described previously ([@B25]). Briefly, we used an open irrigated-tip catheter (Thermocool \[Johnson & Johnson, Inc., Diamond Bar, CA, United States\] or Coolflex \[St. Jude Medical\]; 30--35W, 47°C) to deliver radiofrequency energy for the ablation under 3D electroanatomical mapping (NavX, St. Jude Medical; CARTO3, Johnson & Johnson) merged with the 3D spiral CT. All patients underwent a CPVI in both groups. After CPVI, bidirectional block was confirmed in all patients. Extra-PV ablation was performed based on the virtual ablation outcome in the computational modeling-guided ablation group and was based on the operator's discretion in the empirical ablation group. The procedure was completed when there was no immediate recurrence of AF after cardioversion with an isoproterenol infusion (up to 5 μg/min). All RFCA procedures were performed by an operator with over 10 years of experience.

Post-ablation Management and Follow-Up {#S2.SS5}
--------------------------------------

After the procedure, we maintained AADs for 3 months in 58.3% of the included patients, as the majority had longstanding persistent AF (78% of included patients). Then, we tried to stop AAD if there was no recurred AF in the post-procedure 3^*rd*^ month Holter. Patients visited the outpatient clinic at one, three, six, and 12 months after the RFCA or whenever symptoms occurred. All patients underwent electrocardiography at each visit, and 24-h Holter recording was performed at 3, 6, and 12 months, and every 6 months thereafter, according to the 2012 Heart Rhythm Society/European Heart Rhythm Association/European Cardiac Arrhythmia Society Expert Consensus Statement ([@B2]). When patients reported palpitations, Holter or event monitor recordings were obtained to check for arrhythmia recurrence. We defined recurrence as any episode of AF or atrial tachycardia (AT) lasting for at least 30 s. Any electrocardiography documentation of an AF recurrence after a 3 months blanking period was diagnosed as a clinical recurrence.

Statistical Analysis {#S2.SS6}
--------------------

Continuous variables were compared with a Student's *t*-test, and categorical variables were compared with either the chi-square test or Fisher's exact test, as appropriate. The primary endpoint was the freedom from any atrial arrhythmias during the follow-up after a 3- month blanking period. The time to recurrence and arrhythmia-free survival were assessed with a Kaplan--Meier analysis, and differences were calculated with the log-rank test. To assess the factors associated with a post-RFCA clinical recurrence of AF, we used a Cox proportional-hazard model regression analysis. *p*-Values of \< 0.05 were considered statistically significant. All statistical analyses were performed using SPSS version 25.0 software (SPSS, Inc., Chicago, IL, United States).

Results {#S3}
=======

Baseline Characteristics {#S3.SS1}
------------------------

We enrolled 118 patients with persistent AF for catheter ablation in the CUVIA AF trial. Among them, 10 were excluded due to a failed virtual ablation before starting the clinical procedure (*n* = 6), wrong patient selection (*n* = 2), or upon patient request (*n* = 2); finally, 108 patients (95.2%) were randomized ([Figure 1](#F1){ref-type="fig"}). All included patients initiated the clinical AF ablation procedure after finishing the virtual AF ablation. Eventually, 53 patients were properly and randomly allocated to the computational modeling-guided ablation group, and 55 were allocated to the empirical ablation group ([Figure 1](#F1){ref-type="fig"}). The patient characteristics are summarized in [Table 1](#T1){ref-type="table"}. The mean age was 61 years, 77% were male, and the overall follow-up duration was 31.5 months. The proportion of longstanding PeAF (sustaining more than 1 year) was 78% (83.0% in the modeling-guided ablation group vs. 72.7% in the empirical ablation group, *p* = 0.249). The mean CHA~2~DS~2~-VASc score was 2.0 ± 1.9 and mean LA dimension 45.1 ± 4.4 mm. There were no statistically significant differences in the patient characteristics between the groups.

Virtual Ablation Outcome {#S3.SS2}
------------------------

Per the study protocol, a virtual ablation was performed in all included patients before starting the clinical AF ablation; however, the results were blinded for the empirical ablation group. The pre-ablation computing time for simulating the five virtual ablation strategies described previously was 166 ± 11 min. One hour was required for the heart CT segmentation with a semi-automatic method and settings of five different virtual ablation lesion sets by the manual method. Computing the virtual AF induction and five protocol-based virtual AF ablation lesions required one more hour, and an additional 30 min was required for calculating the CFAE area. The outcomes of the virtual AF ablation are summarized in [Table 2](#T2){ref-type="table"}. We determined the virtual AF termination by waiting 25 s after the virtual AF ablation. Among the five different virtual ablation lesion sets, the POBI and AL ablation after the CPVI \[CPVI + POBI + AL\] had the highest AF termination rate (81.5%, *p* \< 0.001 vs. CPVI alone) and shortest time to AF termination (16.8 ± 5.7 s). Virtual ablation of the RL and LLI after the CPVI \[CPVI + RL + LLI\] had the second highest termination rate (73.1%, *p* \< 0.001 vs. CPVI alone) within 25 s. The virtual AF termination rates were followed by a POBI after the CPVI \[CPVI + POBI\] (28.7%, *p* \< 0.001 vs. CPVI), CPVI alone (11.1%), and CFAE ablation after the CPVI \[CPVI + CFAE\] (8.3%, [Table 2](#T2){ref-type="table"}). There was no significant difference in the virtual ablation outcome between the \[CPVI + CFAE\] and \[CPVI alone\] groups.

###### 

Virtual ablation outcomes.

                                **Overall (*N* = 108)**   **Simulation-guided ablation (*N* = 53)**   **Empirical ablation (*N* = 55)**   ***p*-Value**
  ----------------------------- ------------------------- ------------------------------------------- ----------------------------------- ---------------
  Conduction velocity (m/s)     0.41 ± 0.11               0.40 ± 0.07                                 0.41 ± 0.14                         0.615
  APD~90~ (ms)                  213 ± 2                   213 ± 2                                     213 ± 3                             0.618
  AF termination rate (%)                                                                                                                 
   CPVI                         11.1 (12/108)             9.4 (5/53)                                  12.7 (7/55)                         0.761
   CPVI + POBI                  28.7 (31/108) ^∗^         34.0 (18/53) ^∗^                            23.6 (13/55)                        0.289
   CPVI + POBI + AL             81.5 (88/108) ^∗^         83.0 (44/53) ^∗^                            80.0 (44/55) ^∗^                    0.806
   CPVI + RL + LLI              73.1 (79/108) ^∗^         75.5 (40/53) ^∗^                            70.9 (39/55) ^∗^                    0.667
   CPVI + CFAE                  8.3 (9/108)               7.5 (4/53)                                  9.1 (5/55)                          1
  Time to AF termination (ms)                                                                                                             
   CPVI                         23914 ± 3466              24017 ± 3354                                23815 ± 3599                        0.763
   CPVI + POBI                  21893 ± 5471              21463 ± 5719                                22307 ± 5240                        0.426
   CPVI + POBI + AL             16792 ± 5672              16478 ± 5750                                17094 ± 5633                        0.575
   CPVI + RL + LLI              17701 ± 5770              17199 ± 5949                                18185 ± 5604                        0.378
   CPVI + CFAE                  24170 ± 3041              24319 ± 2686                                24018 ± 3385                        0.619

∗

p

\< 0.001 compared with the CPVI of each group.APD

90

, action potential duration of 90% repolarization; CPVI, circumferential pulmonary vein isolation; POBI, posterior box isolation; AL, anterior line; RL, roof line; LLI, left lateral isthmus line; CFAE, complex fractionated atrial electrogram guided ablation.

Comparison of Procedural Characteristics {#S3.SS3}
----------------------------------------

The procedural results and clinical outcomes are summarized in [Table 3](#T3){ref-type="table"}. The total procedure times, ablation times, and complication rates did not significantly differ between the groups. The AAD maintenance rates did not significantly differ between the two groups (45.3% in the computational modeling-guided ablation group vs. 32.7% in the empirical ablation group, *p* = 0.184). Compared to the modeling-guided ablation group, the ablation lesion sets with the CPVI alone were more common (30.9 vs. 1.9%, *p* \< 0.001), while additional RL and LLI ablation after the CPVI \[CPVI + RL + LLI\] was less common (23.6 vs. 43.4%, *p* = 0.041) in the empirical ablation group. The bidirectional block rates for each linear ablation lesion did not significantly differ between the two groups ([Table 3](#T3){ref-type="table"}).

###### 

Procedure-related characteristics and the clinical rhythm outcomes.

                                                      **Overall (*N* = 108)**   **Simulation-guided ablation (*N* = 53)**   **Empirical ablation (*N* = 55)**   ***p*-Value**
  --------------------------------------------------- ------------------------- ------------------------------------------- ----------------------------------- ---------------
  Procedure time (min)                                264 ± 89                  256 ± 69                                    272 ± 105                           0.403
  Ablation time (sec)                                 5122 ± 2575               4955 ± 2804                                 5273 ± 2368                         0.510
  Fluoroscopic time (min)                             57 ± 30                   59 ± 31                                     55 ± 30                             0.523
  Complication rate,% (n)                             4.2% (4/108)              4.4% (2/53)                                 4.0% (2/55)                         0.900
  AAD utilization rate at discharge,% (n)             58.3% (63/108)            64.2% (34/53)                               52.7% (29/55)                       0.233
  AAD utilization rate after 3 months,% (n)           53.7% (58/108)            64.2% (34/53)                               43.6% (24/55)                       0.108
  AAD utilization at clinical recurrence,% (n)        38.9% (42/108)            45.3% (24/53)                               32.7% (18/55)                       0.184
  Class Ic AAD,% (n)                                  22.2% (24/108)            28.3% (15/53)                               16.4% (9/55)                        0.138
  Class III AAD,% (n)                                 18.5% (20/108)            18.9% (10/53)                               18.2% (10/55)                       0.928
  Procedural lesion set,% (n)                                                                                                                                   
   CPVI                                               16.7% (18/108)            1.9% (1/53)                                 30.9% (17/55)                       **\<0.001**
   CPVI + POBI                                        6.5% (7/108)              11.3% (6/53)                                1.8% (1/55)                         0.058
   CPVI + POBI + AL                                   38.0% (41/108)            39.6% (21/53)                               36.4% (20/55)                       0.843
   CPVI + RL + LLI                                    33.3% (36/108)            43.4% (23/53)                               23.6% (13/55)                       **0.041**
   CPVI + CFAE                                        5.6% (6/108)              3.8% (2/53)                                 7.3% (4/55)                         0.679
  Bidirectional block rates of linear lesions                                                                                                                   
   POBI,% (n)                                         56.3% (27/48)             55.6% (15/27)                               57.1% (12/21)                       0.914
   RL,% (n)                                           78.6% (66/84)             72.0% (36/50)                               83.3% (30/34)                       0.157
   AL,% (n)                                           85.4% (35/41)             76.2% (16/21)                               95.0% (19/20)                       0.093
   LLI,% (n)                                          44.4% (16/36)             39.1% (9/23)                                53.8% (7/13)                        0.408
   Early recurrence,% (n)                             31.5% (34/108)            28.3% (15/53)                               34.5% (19/55)                       0.490
  Clinical recurrence,% (n)                           30.6% (33/108)            20.8% (11/53)                               40.0% (22/55)                       **0.030**
   CPVI                                               22.2% (4/18)              0% (0/1)                                    23.5% (4/17)                        0.468
   CPVI + POBI                                        0% (0/7)                  0% (0/6)                                    0% (0/1)                            \-
   CPVI + POBI + AL                                   26.8% (11/41)             23.8% (5/21)                                30.0% (6/20)                        0.664
   CPVI + RL + LLI                                    41.7% (15/36)             21.7% (5/23)                                76.9% (10/13)                       **\<0.001**
   CPVI + CFAE                                        16.7% (1/6)               0% (0/2)                                    25.0% (1/4)                         0.541
  Clinical recurrence as AT,% (n)                     33.3% (11/33)             9.1% (1/11)                                 45.5% (10/22)                       **0.038**
  Clinical recurrence requiring cardioversion,% (n)   16.7% (18/108)            15.1% (8/53)                                18.2% (10/55)                       0.670
  Final sinus rhythm,% (n)                            93.5% (101/108)           98.1% (52/53)                               89.1% (49/55)                       0.058
  Final sinus rhythm without AADs,% (n)               58.3% (63/108)            52.8% (28/53)                               63.6% (35/55)                       0.259

AAD, antiarrhythmic drug; AL, anterior line; CFAE, complex fractionated atrial electrogram guided ablation; CPVI, circumferential pulmonary vein isolation; LLI, left lateral isthmus line; POBI, posterior box isolation; RL, roof line. Bold values indicate statistical significance at

p

\< 0.05.

Primary Outcome {#S3.SS4}
---------------

During the 37.1 ± 11.6 months of follow-up, the early recurrence rate within 3 months after the procedure did not significantly differ between the computational modeling-guided ablation group (28.3%) and empirical ablation group (34.5%, *p* = 0.490). However, the clinical recurrence rate after 3 months of catheter ablation was significantly lower in the modeling-guided ablation group (20.8%) than in the empirical ablation group (40.0%, *p* = 0.030, [Table 3](#T3){ref-type="table"}). A Kaplan--Meier analysis showed a significantly lower recurrence of AF/AT in the modeling-guided ablation group than in the empirical ablation group (log-rank *p* = 0.042, [Figure 3A](#F3){ref-type="fig"}). This difference was significant in the patients who were taking AADs after the catheter ablation (log-rank *p* = 0.004, [Figure 3B](#F3){ref-type="fig"}), but not in those without AADs (log-rank *p* = 0.204, [Figure 3C](#F3){ref-type="fig"}). The presence of bidirectional block of the linear ablation lesions did not affect the clinical recurrence rate (23.1% in the modeling-guided group vs. 39.4% in the empirical ablation group, *p* = 0.138). Using a multivariable-adjusted Cox proportional hazards model regression analysis, compared with the empirical AF ablation, we found that the computational modeling-guided AF ablation reduced the clinical recurrence rate by 71% (HR 0.29 \[0.12--0.69\], *p* = 0.005, [Table 4](#T4){ref-type="table"}). In the sub-group analyses, the computational modeling-guided AF ablation showed better trends of rhythm outcome in the male individuals, non-obese individuals, patients with a left ventricular ejection fraction of ≥ 50%, E/Em of \< 15, LA dimension of \< 50 mm, and those without hypertension or diabetes ([Figure 4](#F4){ref-type="fig"}).

![Kaplan--Meier curves according to patients with AAD usage. **(A)** Overall patients. **(B)** Patients with maintaining AAD use after catheter ablation. **(C)** Patients without maintaining AAD use after catheter ablation. AAD, antiarrhythmic drug.](fphys-10-01512-g003){#F3}

###### 

Factors associated with a post-RFCA clinical recurrence of AF (Cox proportional-hazard model regression analysis).

  **Variables**                    **Univariable adjusted**   **Multivariable adjusted**                       
  -------------------------------- -------------------------- ---------------------------- ------------------- -----------
  Male                             0.86 (0.35--2.07)          0.728                        0.98 (0.37--2.63)   0.966
  Age (years)                      0.99 (0.96--1.03)          0.859                        0.97 (0.93--1.01)   0.128
  AF duration                      1.00 (0.99--1.01)          0.397                        1.00 (0.99--1.01)   0.608
  CHA~2~-DS~2~-VASc                0.97 (0.79--1.19)          0.750                                            
  Heart failure                    0.41 (0.10--1.71)          0.220                                            
  Hypertension                     1.19 (0.60--2.38)          0.617                                            
  Diabetes                         0.70 (0.27--1.82)          0.467                                            
  Previous stroke/TIA              1.25 (0.54--2.88)          0.603                                            
  Vascular disease                 0.84 (0.30--2.40)          0.747                                            
  Baseline LA AP diameter (mm)     1.01 (0.96--1.06)          0.714                        1.02 (0.97--1.07)   0.523
  Baseline LV EF (%)               1.01 (0.97--1.06)          0.663                                            
  Baseline E/Em                    0.88 (0.73--1.02)          0.108                                            
  Post-RFCA AAD use                2.09 (0.92--4.30)          0.082                        2.46 (0.57--4.63)   0.102
  **Simulation-guided ablation**   0.48 (0.23--0.99)          **0.048**                    0.29 (0.12--0.69)   **0.005**

AAD, antiarrhythmic drug; CI, confidence interval; E, early diastolic transmitral flow velocity; Em, early diastolic mitral annular velocity; HR, hazard ratio; LA AP, left atrial anterior--posterior; LV EF, left ventricular ejection fraction; PeAF, persistent atrial fibrillation; RFCA, radiofrequency catheter ablation; TIA, transient ischemic attack; simulation-guided ablation, virtual

in silico

model guided catheter ablation. Bold values indicate statistical significance at

p

\< 0.05.

![Age- and sex-adjusted HR for post-RFCA clinical recurrence of AF according to subgroups (Cox proportional-hazard model regression analysis). AF, atrial fibrillation; AP diameter, antero-posterior diameter; BMI, body mass index; DM, diabetes mellitus; EF, ejection fraction; E/Em, the ratio of early transmitral flow velocity (E) to early mitral annular velocity (Em); HR, hazard ratio; HTN, hypertension.](fphys-10-01512-g004){#F4}

Secondary Outcome {#S3.SS5}
-----------------

Among a total of 33 patients with clinical recurrence, 22 had AF and 11 had AT at the time of the recurrence. Among the patients with clinical recurrence, the proportion of AT (9.1% \[1/11\] vs. 45.5% \[10/22\], *p* = 0.038) were lower in computational modeling-guided ablation group, but those requiring cardioversion (72.7% \[8/11\] vs. 45.5% \[10/22\], *p* = 0.147) did not significantly differ between the two groups ([Table 3](#T3){ref-type="table"}). Among all included patients, 15.1% (8/53) of those in the modeling-guided ablation group and 18.2% (10/55) of those in the empirical ablation group underwent cardioversion to control AAD resistant recurred atrial arrhythmias ([Table 3](#T3){ref-type="table"}). Repeat ablation procedures were performed in 14 patients (11.3% in the modeling-guided ablation group vs. 14.5% in the empirical ablation group, *p* = 0.622), and reconnected PV potentials were found in 21.4% (3/14) in the modeling-guided ablation group and 42.9% (6/14) in the empirical ablation group (*p* = 0.240).

Discussion {#S4}
==========

Main Findings {#S4.SS1}
-------------

In this study, we generated a highly efficient patient-specific computational AF modeling, which could be applied to the clinical AF ablation procedure. In this first multi-center prospective randomized clinical trial of 118 patients with PeAF (77.8% with longstanding PeAF), the modeling-guided ablation group applied the lesion set of the fastest virtual AF termination after comparing five different virtual lesion sets. During the mean 31.5 months follow-up, the computational modeling-guided ablation results were superior to the empirical catheter ablation results regarding the rhythm outcome. The rhythm outcome of the computational modeling-guided ablation showed better trends in patients with a less structurally remodeled atrium.

PeAF Ablation: Unanswered Continuous Challenge {#S4.SS2}
----------------------------------------------

Atrial fibrillation catheter ablation has been proven to reduce the AF burden, heart failure mortality ([@B19]), and stroke risk, and it also improves the cognitive and renal function ([@B27]; [@B2]). Although the CPVI is a cornerstone lesion of AF ablation in both paroxysmal and PeAF ([@B30]), the 1-year rhythm outcome is not satisfactory in patients with PeAF with multiple extra-PV triggers ([@B22]). Thus, an empirical extra-PV ablation for a substrate modification has been applied in patients with PeAF for many years and is known to be beneficial ([@B33]). However, the recent prospective randomized clinical trial, STAR-AF2, failed to prove its usefulness ([@B30]). Therefore, personalized extra-PV AF rotors or drivers have been traced by clinical investigators ([@B21]). We also demonstrated the effectiveness of a virtual ablation targeting AF spiral wave reentries represented by a high dominant frequency area in the computational modeling study ([@B11]), but the majority were non-stationary rotors that were affected by the local conduction velocity ([@B21]). Currently, catheter ablation targeting these non-stationary hypothetical triggers is controversial in patients with PeAF ([@B2]). Rather, we need a more reproducible and clinically feasible sophisticated mapping technique reflecting the patient-specific anatomy and electrophysiology that affects the AF wave-dynamics.

Current Technology of Computational AF Modeling {#S4.SS3}
-----------------------------------------------

Cardiac computational modeling has a growing role and allows for the non-invasive identification of spiral wave reentries in AF ([@B17]). Although the contemporary clinical 3D electroanatomical mapping system has enabled contact electrogram-based mapping of the atrium in detail, it is not possible to identify non-stationary AF drivers by point-to-point catheter mapping. The entire chamber mapping, such as focal impulse and rotor mapping (FIRM) ([@B21]) or panoramic mapping ([@B6]), has a limitation in its spatial resolution. In recent years, high-performance computational simulation technology has enabled patient-specific AF modeling that reflects MRI-defined fibrosis, the fiber orientation, and the tissue thickness, and has been clinically applied ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}) ([@B12]). With this sophisticated computational modeling, high-density entire chamber mapping of AF, reflecting a personalized anatomy and histology, is possible. However, the long computing time is the major limitation for the application of this sophisticated and realistic AF modeling to clinical practice. Therefore, we generated a high-speed high-density (half million nodes) chamber-centric AF computational modeling integrated with the patient-specific atrial anatomy. A graphics processing unit system was used to sufficiently improve the computational speed to be applicable for clinical AF ablation ([@B10]). We also validated its reproducibility in a retrospective clinical study ([@B10]) and feasibility ([@B25]) and efficacy in this prospective clinical study. Although it is technically possible, we did not incorporated patient-specific atrial fibrosis or fiber orientation in this study because of computational speed issue. In order to apply more sophisticated patient-specific information that is acquired during the on-site procedure, the technological innovation that can increase the computation speed is expected. However, AF is a multifactorial systemic degenerative disease and its rhythm outcome can be affected by metabolic factors, such as obesity ([@B18]), pericardial fat volume ([@B13]) and obstructive sleep apnea ([@B4]). Since CUVIA computational modeling reflects the characteristics of patients' atrium proper, its predictive value might be higher in non-obese patients with less remodeled atria.

Limitations and Future Clinical Applications {#S4.SS4}
--------------------------------------------

Although we applied the patient-specific atrial anatomy for our AF modeling study, it was a monolayer homogeneous model. This modeling study is only related to anatomical factor and their clear relation with AF activation patterns remains unclear. While the atrial thickness variations, epicardial conduction ([@B8]), and myofiber orientation could affect the cardiac wave propagation ([@B9]), the wave propagation pattern of the monolayer model is very similar to that of the bilayer model ([@B16]). Reflection of the atrial wall thickness may improve the cardiac wave dynamics analyses as well as the RF energy titration during clinical AF ablation procedures in the future. A more realistic AF computational modeling application is under way, applying the contact electrogram voltage and local activation pattern acquired during the AF ablation procedure and the atrial wall thickness obtained from atrial imaging. Therefore, it is challenging to further reduce the computing simulation time to generate an upgraded system applicable in *in situ* procedures. Although we used irrigated-tip catheters for clinical AF ablation, we did not use contact-force technology nor ablation lesion index in this study. Additionally, although patients were followed as the guideline ([@B2]), 24-h Holter recording at 3, 6, 12 months is relatively overestimates the success, therefore, careful interpretation is needed ([@B29]). The lack of a continuous rhythm recording, such as implantable loop recorder, may alter the outcome by detection of silent and/or short AF recurrences. Although randomization was performed by a central randomization service independent of investigators, the number of patients with AADs after the procedure tend to be more in computational modeling-guided ablation group than in empirical ablation group; however, the difference was not statistically significant (*p* \> 0.10). Therefore, careful interpretation is needed in this respect. In order to make this study outcome more appealing and realistic, a larger study population will be needed. The individuals in this study were limited to PeAF patients, and the outcome of this study cannot be extrapolated to other types of AF or the entire AF population.

Conclusion {#S5}
==========

We tested the feasibility and efficacy of highly efficient patient-specific computational AF modeling in a multi-center prospective randomized clinical trial. During the mean 31.5 months follow-up, the computational modeling-guided ablation was superior to the empirical catheter ablation regarding the rhythm outcome. The rhythm outcome of the computational modeling-guided ablation showed better trends in patients with a less structurally remodeled atrium.
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